elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26828930-86042ED6-5C89-44B9-A707-88A4805575DB
Q26828930-86042ED6-5C89-44B9-A707-88A4805575DB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26828930-86042ED6-5C89-44B9-A707-88A4805575DB
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
P2860
Q26828930-86042ED6-5C89-44B9-A707-88A4805575DB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26828930-86042ED6-5C89-44B9-A707-88A4805575DB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
16322a5d5a5169fc6a3c530288443580d0962ee1
P2860
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer